Isatuximab

Isatuximab
	Isatuximab (pale blue) binding CD38 (purple). PDB: 4CMH
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD38
Clinical data
Trade names	Sarclisa
Other names	SAR-650984, isatuximab-irfc
AHFS/Drugs.com	Monograph
MedlinePlus	a620023
License data	US DailyMed: Sarclisa;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous
Drug class	Antineoplastic
ATC code	L01FC02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	1461640-62-9;
DrugBank	DB14811;
ChemSpider	none;
UNII	R30772KCU0;
KEGG	D11050;
Chemical and physical data
Formula	C6456H9932N1700O2026S44
Molar mass	145190.99 g·mol−1

Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma.

The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs).

Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. It entered in Phase II trials for multiple myeloma and T-cell leukemia in 2015.